The company have substantially improved its development of an novel treatment for cardiac amyloidosis, employing the investigational drug. Preliminary clinical results suggests significant improvements for patients diagnosed from a serious condition. This effort highlights the company’s dedication to addressing unmet medical needs in this heart f